Current Edition

Current Features

Harnessing The Power of Solid Form and Particle Engineering to Overcome Solubility and Bioavailability Challenges

An Interview with Veranova’s Craig Grant Persistent challenges in poor solubility and low bioavailability have long impeded the pharmaceutical development pipelin...
Continue Reading →
Volume 15 Issue 4

Ensuring a Robust Strategy to Navigate the Development of Challenging APIs

Small molecules as therapeutic agents have played a significant role in the improvement of human health and wellbeing since the discovery and commercialisation of mo...
Continue Reading →
Volume 15 Issue 4

Promising Platforms

How novel processing platforms incorporating new technologies can help to accelerate the development of cell and gene therapy processing, overcoming key industry cha...
Continue Reading →
Volume 15 Issue 4

Mastering the Immune Response: Immunogenicity Management in Biologics

The advent of therapeutic proteins and gene therapies has been a beacon of hope for treating complex diseases. Yet, these innovative treatments often face the signif...
Continue Reading →
Volume 15 Issue 4

Making Solid Oral Dosage Forms a Reality for Cannabinoid-based Drug Development

In the rapidly growing and evolving cannabinoid space, crafting more patient-centric pharmaceuticals that meet therapeutic needs and convenience is at the forefront ...
Continue Reading →
Volume 15 Issue 2

IPI Speaks with PharmaLex’s Local Affiliate Services Lead on the Rapidly Changing Global Market

Q: Can we start with some insights as to why the Local Affiliate Services solution was established and what its overarching objectives are? A: There is rising dem...
Continue Reading →
Volume 15 Issue 2

Serving the 0.05% of Patients Living with a Rare Disease

Increasing adoption of digital trials and data-driven commercial strategies has laid the foundations for improved pinpointing of treatments and speedier diagnoses. ...
Continue Reading →
Volume 15 Issue 2

Potent Product Manufacturing in a Multi-product Facility

Highly potent drugs are becoming increasingly common in the drug development pipeline. The focus on oncology, rare diseases, and targeted therapies is grow...
Continue Reading →
Volume 15 Issue 1

IPI speaks with experts at PharmaLex on Integrated Product Development

Q: Can we start with a brief history of PharmaLex, what are your key offerings into the industry? A: PharmaLex was established 25 years ago with a vision to make ...
Continue Reading →
Volume 15 Issue 1

Navigating the Changing Oral Solid Dose Landscape

Oral solid dose (OSD) forms have accounted for the lion’s share of the pharmaceutical market for decades, thanks to their easy administration leading to patient conv...
Continue Reading →